Emily K. Bergsland, MD

Vice President

Medical Oncology, University of California, San Francisco School of Medicine

She also holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. 

She earned her medical degree from the University of Minnesota and completed an internship, residency, and chief residency in internal medicine at UCSF. She subsequently completed a fellowship in Medical Oncology and was a Molecular Medicine fellow before joining the UCSF faculty in 1998. 

Dr. Bergsland is a specialist in gastrointestinal oncology at the UCSF Helen Diller Comprehensive Cancer Center. Her expertise extends to the treatment of gastrointestinal cancers, with an emphasis on colorectal and neuroendocrine malignancies.

In her research, she focuses on developing and testing novel cancer therapies. She has also written extensively on the evolution of neuroendocrine tumor treatment. Dr. Bergsland has led numerous clinical studies in patients with gastrointestinal malignancies. Her current efforts are focused on clinical and translational research related to neuroendocrine tumors. At a national level, Dr. Bergsland is a member of the Neuroendocrine Tumor Task force for the National Cancer Institute and a member of the NCCN NET guidelines panel. She is also the study chair for a national study of a novel treatment for patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.

Dr. Bergsland and is the Vice President of the North American Neuroendocrine Tumor Society (NANETS).

More about Dr. Bergsland